Treatment of Systemic Sclerosis in Raynaud's Phenomenon
In patients with systemic sclerosis, Raynaud's phenomenon (SSc-RP) is a distinct vascular
complication that requires targeted management. The clinical goal is to reduce the burden
of attacks and measurably improve vascular outcomes.
Clinical Scenario
This protocol addresses Raynaud's phenomenon occurring in the context of systemic
sclerosis. The presence of SSc-RP defines a specific sub-population where
vasomotor attacks are driven by the underlying connective tissue disease and demand
a targeted therapeutic approach.
Therapeutic Targets
Successful management aims for improvement in the Raynaud's condition score,
along with meaningful reduction in the daily frequency and duration of Raynaud's
phenomenon attacks.
Treatment Approach (partial)
The evidence-based regimen for SSc-RP involves a specific class of agents with
demonstrated benefit on vascular outcomes — the complete protocol, including sequencing
and full clinical guidance, is available via the link below.
References
DOI: 10.1136/ard-2024-226430
Dihydropyridine-type calcium antagonists, usually oral nifedipine, should be used as first-line therapy for SSc-RP.
PDE5 inhibitors should also be considered for treatment of SSc-RP.
The PDE5 inhibitor group showed an overall improvement in Raynaud's condition score compared with placebo.
Significant differences were also noted in daily frequency of RP attacks and daily duration of RP attacks in minutes.
View source ↗